Is anemia a common side effect of lurbinectedin?
Yes, anemia is a common side effect of lurbinectedin (brand name Zepzelca), occurring in 54% of patients in clinical trials, with severe (grade 3/4) cases in 20%.[1][2]
How often does anemia occur with lurbinectedin?
In the pivotal PM14-128 trial for relapsed small cell lung cancer, anemia affected 54% of patients overall. Grade 3/4 anemia hit 20%, often requiring transfusions or dose adjustments. Median time to onset was 22 days, resolving in most cases after treatment interruption.[1][2][3]
Why does lurbinectedin cause anemia?
Lurbinectedin inhibits RNA polymerase II, damaging rapidly dividing cells in bone marrow and leading to myelosuppression. This reduces red blood cell production, mimicking effects of platinum chemotherapy often used prior.[1][4]
How is anemia managed during lurbinectedin treatment?
Monitor complete blood counts before each cycle and weekly if grade 3/4 occurs. Hold dosing for grade 2 anemia; reduce by 25% for recurrence or grade 3/4. Transfusions support severe cases. Prophylactic growth factors like erythropoietin are not routinely recommended due to thrombosis risk.[1][2]
What other blood-related side effects occur?
Neutropenia (58%, grade 3/4 in 33%) and thrombocytopenia (45%, grade 3/4 in 13%) are also common, often overlapping with anemia in 20-30% of patients. These drive 52% of dose reductions.[1][3]
How does lurbinectedin compare to topotecan for anemia risk?
Lurbinectedin shows lower anemia rates (54% all-grade vs. 70% with topotecan) and fewer transfusions (20% vs. 40%) in head-to-head trials, contributing to its FDA approval over topotecan.[1][3]
[1]: Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, https://www.zepzelca.com/
[2]: Trigo J et al. Lancet Oncol 2020;21:1443-1451, https://doi.org/10.1016/S1470-2045(20)30490-4
[3]: FDA approval summary for Zepzelca, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[4]: Paz-Ares L et al. J Clin Oncol 2021;39:2989-2999, https://doi.org/10.1200/JCO.21.00196